This upregulation enhances tumor cell recognition by antigen-specific CD8 + T cells, particularly when paired with NY-ESO-1-directed vaccines, leading to delayed tumor growth compared to standalone treatments [19]. This evidence concerns the gene CD8A and neoplasm.